AKT1 and nonpapillary renal cell carcinoma: Our previous data demonstrating that PI3Kβ-specific inhibitors decrease phosphorylation levels of key downstream effectors in the PI3K-AKT pathway (pAKT-S473 and pS6-S235/236) in SETD2 deficient ccRCC-derived cells prompted us to further explore the molecular mechanism connecting SETD2 to PI3Kβ.